tbuckley/cabot-search huggingface dataset:
Abstract 181: Cardiac Hypertrophy And Heart Failure In K-channel Ancillary Subunit Depleted Mice
Authors: Torsten K Roepke, Ulrike Lisewski, Leonhard Schleussner, Carolin Gaertner, Clemens Koehncke
Journal: Circulation Research (2013)

Down regulation of cardiac K+ currents has been described in hypertrophic heart disease and heart failure. However, so far no mutations in potassium channel genes have been found in patients with cardiac hypertrophy/heart failure. It therefore remains controversial whether K+ current down regulation represents a primary cause of cardiac hypertrophy/heart failure or epiphenomena. KCNE2 is a voltage gated potassium channel ancillary subunit that is associated with inherited and acquired long QT syndrome. We recently developed KCNE2-/- mice. KCNE2-/- mice have normal cardiac morphology and function at 3-6 months of age despite a repolarization defect caused by disruption of IKslow, 1 and Ito, f. However, aged KCNE2-/- mice (12 months and older) develop significant cardiac hypertrophy and severe heart failure assessed by echocardiography, isolated heart (Langendorff) and reduced cellular shortening (IonOptix). Furthermore, after Angiotensin II stimulation 3-6 months old KCNE2-/- mice also develop significant cardiac hypertrophy and fibrosis compared to age-matched KCNE2+/+ siblings. Taqman PCR revealed molecular remodelling in hypertrophied failing KCNE2-/- hearts with induction of the fetal gene program (ANF re-expression), significant up regulation of Sodium-Calcium Exchanger (NCX) and significant down regulation of phospholamban. Alterations in Calcium handling proteins were also recapitulated on protein level by Western Blotting. Furthermore, electrophysiological studies by patch clamp analysis of isolated cardiomyocytes revealed a decrease in current densities of the L-type Ca2+-current and a strongly diminished response to isoprenaline stimulation in hypertrophied failing KCNE2-/- cardiomyocytes. We therefore conclude that primary disruption of repolarizing Kv currents by KCNE2 deletion leads to altered Calcium handling and consecutive induction of cardiac hypertrophy/heart failure.
Value-Based Payment Models for Community Health Centers
Authors: Jay Bhatia, Rachel Tobey, Michael Hochman
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum: The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance
Authors: Alejandro Villagra, Fengdong Cheng, Hong-Wei Wang, Ildelfonso Suarez, Michelle Glozak, Michelle Maurin, Danny Nguyen, Kenneth L Wright, Peter W Atadja, Kapil Bhalla, Javier Pinilla-Ibarz, Edward Seto, Eduardo M Sotomayor
Journal: Nature Immunology (2009)
Deciphering the connection of tumor genetics, tumor immune cell infiltration and prognosis in breast cancer
Authors: J. Budczies, B.V. Sinn, B.M. Pfitzner, S. Villegas-Angel, B. Ingold-Heppner, S. Wienert, F. Klauschen, C. Denkert
Journal: Annals of Oncology (2017)
A Genomic Signature Predicting Venetoclax Treatment Response in AML Identified By Protein Network Mapping and Validated By Ex Vivo Drug Sensitivity Testing: A Beat AML Project Study
Authors: Leylah Drusbosky, Taher Abbasi, Shireen Vali, Saumya Radhakrishnan, Neeraj Kumar Singh, Shahabuddin Usmani, Deepak Parashar, Robinson Vidva, Brian J. Druker, Cristina E. Tognon, Pierrette Lo, Jeffrey W. Tyner, Christopher R. Cogle
Journal: Blood (2016)
Safety and Feasibility of Ultra-Low Dose IL-2 As Graft Versus Host Disease Prophylaxis in Haplo-Identical Stem Cell Transplantation- a Proof of Concept Pilot Study
Authors: Sawa Ito, Prachi Jain, Caroline R Cantilena, Prathima Anandi, Kit Lu, Fariba Chinian, Debbie Draper, Libby Koklanaris, Sara Hauffe, Jeanine Superata, Andra Krauze, David Stroncek, Adams Sharon, Thomas E. Hughes, Pawel Muranski, Minoo Battiwalla, John Barrett
Journal: Blood (2016)
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
Authors: V. Conteduca, D. Wetterskog, M.T.A. Sharabiani, E. Grande, M.P. Fernandez-Perez, A. Jayaram, S. Salvi, D. Castellano, A. Romanel, C. Lolli, V. Casadio, G. Gurioli, D. Amadori, A. Font, S. Vazquez-Estevez, A. González del Alba, B. Mellado, O. Fernandez-Calvo, M.J. Méndez-Vidal, M.A. Climent, I. Duran, E. Gallardo, A. Rodriguez, C. Santander, M.I. Sáez, J. Puente, D. Gasi Tandefelt, A. Wingate, D. Dearnaley, F. Demichelis, U. De Giorgi, E. Gonzalez-Billalabeitia, G. Attard
Journal: Annals of Oncology (2017)

BackgroundThere is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC.MethodsWe optimized ddPCR assays for AR copy number and mutations and retrospectively analyzed plasma DNA from patients recruited to one of the three biomarker protocols with prospectively collected clinical data. We evaluated associations between plasma AR and overall survival (OS) and progression-free survival (PFS) in 73 chemotherapy-naïve and 98 post-docetaxel CRPC patients treated with enzalutamide or abiraterone (Primary cohort) and 94 chemotherapy-naïve patients treated with enzalutamide (Secondary cohort; PREMIERE trial).ResultsIn the primary cohort, AR gain was observed in 10 (14%) chemotherapy-naïve and 33 (34%) post-docetaxel patients and associated with worse OS [hazard ratio (HR), 3.98; 95% CI 1.74–9.10; P < 0.001 and HR 3.81; 95% CI 2.28–6.37; P < 0.001, respectively], PFS (HR 2.18; 95% CI 1.08–4.39; P = 0.03, and HR 1.95; 95% CI 1.23–3.11; P = 0.01, respectively) and rate of PSA decline ≥50% [odds ratio (OR), 4.7; 95% CI 1.17–19.17; P = 0.035 and OR, 5.0; 95% CI 1.70–14.91; P = 0.003, respectively]. AR mutations [2105T>A (p.L702H) and 2632A>G (p.T878A)] were observed in eight (11%) post-docetaxel but no chemotherapy-naïve abiraterone-treated patients and were also associated with worse OS (HR 3.26; 95% CI 1.47–not reached; P = 0.004). There was no interaction between AR and docetaxel status (P = 0.83 for OS, P = 0.99 for PFS). In the PREMIERE trial, 11 patients (12%) with AR gain had worse PSA-PFS (sPFS) (HR 4.33; 95% CI 1.94–9.68; P < 0.001), radiographic-PFS (rPFS) (HR 8.06; 95% CI 3.26–19.93; P < 0.001) and OS (HR 11.08; 95% CI 2.16–56.95; P = 0.004). Plasma AR was an independent predictor of outcome on multivariable analyses in both cohorts.ConclusionPlasma AR status assessment using ddPCR identifies CRPC with worse outcome to enzalutamide or abiraterone. Prospective evaluation of treatment decisions based on plasma AR is now required.Clinical Trial numberNCT02288936 (PREMIERE trial).
<i>AJRCCM</i>: 100-Y<scp>ear</scp> A<scp>nniversary</scp>.Homeward Bound: A Centenary of Home Mechanical Ventilation
Authors: Matthew Hind, Michael I. Polkey, Anita K. Simonds
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Section:ChooseTop of pageAbstract <<EvolutionNegative to Positive Pres...PrevalenceInherited Muscular Dystro...ALSNIV in COPDNIV in BronchiectasisNIV in Cystic FibrosisNIV in Obesity Hypoventil...Palliative NIVInterfacesGlobal Home Ventilation i...ReferencesCITING ARTICLES
Is It Time for Early Cessation of Empirical Antibiotherapy in Patients Presenting with Febrile Neutropenia? Preliminary Results of a Risk-Adapted Approach in a Hematology Clinic
Authors: Ali Hakan Kaya, Emre Tekgunduz, Filiz Bekdemir, Hikmetullah Batgi, Tugcenur Yigenoglu, Bahar Uncu Ulu, Bilge Ugur, Dicle Iskender, Merih Kizil Cakar, Mehmet Sinan Dal, Seval Akpinar, Fatih Demirkan, Fevzi Altuntas
Journal: Blood (2016)
Selecting patients for endovascular treatment of acute stroke
Authors: José G Merino
Journal: BMJ (2017)

New prediction tool will improve decision making at a critical time

Endovascular thrombectomy improves functional outcome in patients with severe stroke due to an occlusion of the internal carotid artery or proximal middle cerebral artery if the procedure is started within six hours from symptom onset. A recent meta-analysis found that, compared with standard treatment, for every 1000 patients undergoing endovascular thrombectomy in addition to standard medical treatment, 167 more will attain a good outcome.1 The benefit is greatest for patients treated in the earliest time windows.2

In many countries, endovascular thrombectomy is the standard of care for eligible patients.3 But provision of this treatment requires expertise and resources that are not available in all hospitals. To improve access, regional systems of care have been reorganised to allow rapid identification and transfer …
Bendamustine Demonstrates Promising Activity in Post-Brentuximab Failure Hodgkin Lymphoma Patients Who Had Also Failed a Prior Autologous HCT and Facilitates Successful Bridging to Allogeneic HCT
Authors: Jean Elcheikh, Radwan Massoud, Elie Fares, Mohamed A Kharfan-Dabaja, Jisr Tamima, Anas Mougharbel, Ali Bazarbachi, Ahmad Ibrahim
Journal: Blood (2016)
Effect of Dexrazoxane on Heart Function Among Long-Term Survivors of Childhood Leukemia and Lymphoma: A Report from the Children's Oncology Group (COG)
Authors: Eric J Chow, David R. Doody, Saro H. Armenian, Sanjeev Aggarwal, K. Scott Baker, Smita Bhatia, Nancy A. Blythe, Louis S. Constine, David R. Freyer, Lisa M. Kopp, Wendy M. Leisenring, Nao Sasaki, Lynda M. Vrooman, Barbara L. Asselin, Cindy L. Schwartz, Steven E. Lipshultz
Journal: Blood (2016)
Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study
Authors: H. Bourgeois, F. Grudé, P. Solal-Céligny, O. Dupuis, E. Voog, G. Ganem, F. Denis, M. Zinger, L. Juhel-Voog, C. Lafond, P. Maillart, O. Capitain, R. Delva, P. Soulié, S. Abadie-Lacourtoisie, V. Guérin-Meyer, M.E. Morin-Meschin, J.M. Commer, A. Gangler, B. d’Aillières, A. Zannetti, E. Bourbouloux, D. Berton-Rigault, S. Lebouvier-Sadot, M. Kaassis, J. Baudon, Y.H. Lam, A. Bizieux, M. Marcq, J. Edeline, F. Le Du, C. Lefeuvre, P. Deguiral, V. Delecroix, E. Blot, J. Egreteau, M.J. Goudier, R. Lamy, M. Ferec, X. Artignan, S. Corbinais, H. Morel, A.C. Hardy-Bessard, C. Alleaume, E. Naudeix, O. Cojocarasu, J.P. Metges, C. Riché, E. Gamelin, D. Déniel-Lagadec, F. Marhuenda, P. Ingrand, J.Y. Douillard
Journal: Annals of Oncology (2017)
Missed Opportunities for Deprescription
Authors: Ismail A. Raslan, Emily G. McDonald, Todd C. Lee
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Abstract 13594: Impact on Clinical Outcomes of Randomization at Community Hospitals Versus Pre-hospital location in STEMI Patients: Insights From the STREAM Study
Authors: Robert C Welsh, Patrick Goldstein, Antonio Carvalho, Miodrag C Ostojic, John Nanas, Yinggan Zheng, Anthony Gershlick, Thierry Danays, Frans Van de Werf, Paul W Armstrong
Journal: Circulation (2015)

Objectives: The STREAM study randomized STEMI pts &lt;3 hrs from symptom onset to primary PCI (pPCI) or a fibrinolysis pharmacoinvasive approach (PI) with rescue for failed fibrinolysis and scheduled angiography for the remainder within 24h. Although most pts were randomized pre-hospital (PH) and admitted to pPCI centres, selected community hospitals (CH) within STEMI networks also participated. Given the inherent delays with inter-hospital transfer, we examined outcomes accordingly to randomization location. Methods: CH pts 358/1866 (19.2%) were compared to PH pts. Results are further categorized according to pts receiving pPCI, PI rescue, PI with scheduled angiography (%’s and medians with 25th-75th percentiles). Results: Overall compared to PH, CH pts had more diabetes (17.8% vs. 11.5%, p=0.001), higher Killip Class &gt;1 (9.4% vs. 5.0%, p=0.002) and TIMI Risk Score ≥5 (18.2% vs. 12.4%, p=0.005). 30-day primary composite endpoint (death, CHF, shock, re-infarction) for CH was 14.9% vs. PH 13.2% (p=0.403). PI pts within CH received less rescue PCI than PH pts (35.1% vs. 42.8%, p=0.062) (table) and it was delayed by approximately 43 min. CH pts undergoing pPCI also had an approximate 31 min delay. After adjusting for TIMI risk score and time from symptom onset, CH pts requiring rescue had worse outcomes compared to PH (OR 2.3, 95% CI, 1.2-4.6); However no difference in outcomes existed between CH and PH pts in those undergoing pPCI (p interaction=0.027). PI pts receiving scheduled cath from CH and PH had comparable times to cath (17.7 vs. 18.7 hours) and low primary composite event rates (6.2% vs 8.0%). Conclusion: Within STREAM CH pts had higher baseline risk but overall similar outcomes to those randomized PH. Despite higher baseline risk, CH pts with successful fibrinolysis and scheduled angiography or those who underwent primary PCI had similar outcomes to PH. The worse outcomes in CH rescue pts emphasizes the need to identify and expeditiously treat those pts needing rescue PCI.
Effects of Antiplatelet Treatment with Aspirin (ASA) on Platelet Reactivity in Patients with Essential Thrombocythemia
Authors: Marina Marchetti, Sara Gamba, Cinzia Giaccherini, Cristina Verzeroli, Laura Russo, Carmen Julia Tartari, Alfonso Vignoli, Guido Finazzi, Alessandro Rambaldi, Anna Falanga
Journal: Blood (2016)
A Comprehensive Safety Evaluation of 68Ga-Labeled Ligand Prostate-Specific Membrane Antigen 11 PET/CT in Prostate Cancer
Authors: Julie B. Nielsen, Helle D. Zacho, Uwe Haberkorn, Karin M. Nielsen, Katja Dettmann, Niels C. Langkilde, Lars J. Petersen
Journal: Clinical Nuclear Medicine (2017)

Purpose The aim of this study was to evaluate the clinical safety profile of the 68Ga-PSMA-11 ligand for PET/CT imaging in prospective clinical trials. Methods Eighty-eight patients with newly diagnosed or recurrent prostate cancer participated in 2 prospective trials. Safety reporting was identical in the 2 trials. The 68Ga-PSMA-11 ligand was administered as 2 MBq/kg body weight (mean, 9.2 μg, 9.7 nmol). The reporting of clinical adverse events (AEs) and the measurement of blood pressure (BP) and heart rate (HR) were performed prior to injection (baseline); immediately after injection of 68Ga-PSMA-11 (postinjection); at 1, 10, and 60 minutes after injection; and after acquisition of the PET/CT scan (postscan). All hemodynamic assessments were performed in the supine position, except for the postscan measurement (sitting). The patients were interviewed regarding any AEs at baseline, postinjection, or postscan. In addition, the patients were instructed to report any AEs during the investigation and to contact the investigator if AEs occurred during the rest of the day. Adverse events were classified as mild, moderate, or severe by the patients and categorized by the investigator using the CTCAE (Common Terminology Criteria for Adverse Events) version 4.0. Results There were no reported clinical AEs. There were significant decreases in systolic BP (P < 0.001) and HR (P < 0.001) over time. In comparison, the diastolic BP increased significantly (P < 0.001). After removal of the last observation (supine position), there was no time-dependent change in systolic or diastolic BP, but the significant change in HR remained. The mean changes over the entire observation period were minimal (systolic BP, −6 to 5 mm Hg; diastolic BP, −2 to 3 mm Hg; HR, decrease of 5 beats/min). No patients developed hypotension. Fifty-five patients presented with hypertension at baseline, which increased by 1 CTCAE grade in 15 patients and by 2 grades in 2 patients. A large number of cases of asymptomatic (grade 1) bradycardia were observed, primarily in patients with preexisting bradycardia. One patient developed transient grade 1 tachycardia. No patients required medical intervention for cardiovascular perturbations. Conclusions 68Ga-PSMA-11 PET/CT was very well tolerated. We consider 68Ga-PSMA-11 to be safe for human application.
Plasma Biomarkers and Kidney Function Decline in Early and Established Diabetic Kidney Disease
Authors: Steven G. Coca, Girish N. Nadkarni, Yuan Huang, Dennis G. Moledina, Veena Rao, Jane Zhang, Bart Ferket, Susan T. Crowley, Linda F. Fried, Chirag R. Parikh
Journal: Journal of the American Society of Nephrology (2017)

Biomarkers of diverse pathophysiologic mechanisms may improve risk stratification for incident or progressive diabetic kidney disease (DKD) in persons with type 2 diabetes. To evaluate such biomarkers, we performed a nested case-control study ( n =190 cases of incident DKD and 190 matched controls) and a prospective cohort study ( n =1156) using banked baseline plasma samples from participants of randomized, controlled trials of early (ACCORD) and advanced (VA NEPHRON-D) DKD. We assessed the association and discrimination obtained with baseline levels of plasma TNF receptor–1 (TNFR-1), TNFR-2, and kidney injury molecule–1 (KIM-1) for the outcomes of incident DKD (ACCORD) and progressive DKD (VA-NEPHRON-D). At baseline, median concentrations of TNFR-1, TNFR-2, and KIM-1 were roughly two-fold higher in the advanced DKD population (NEPHRON-D) than in the early DKD population (ACCORD). In both cohorts, patients who reached the renal outcome had higher baseline levels than those who did not reach the outcome. Associations between doubling in TNFR-1, TNFR-2, and KIM-1 levels and risk of the renal outcomes were significant for both cohorts. Inclusion of these biomarkers in clinical models increased the area under the curve (SEM) for predicting the renal outcome from 0.68 (0.02) to 0.75 (0.02) in NEPHRON-D. Systematic review of the literature illustrated high consistency in the association between these biomarkers of inflammation and renal outcomes in DKD. In conclusion, TNFR-1, TNFR-2, and KIM-1 independently associated with higher risk of eGFR decline in persons with early or advanced DKD. Moreover, addition of these biomarkers to clinical prognostic models significantly improved discrimination for the renal outcome.
Concomitant chemoradiotherapy using docetaxel, cisplatin, and 5-FU for the patients with advanced squamous cell carcinoma of the temporal bone.
Authors: Kiyoto Shiga, Katsunori Katagiri, Takenori Ogawa, Kengo Kato, Yukinori Asada, Toshimitsu Kobayashi
Journal: Journal of Clinical Oncology (2012)

e16020 Background: Chemotherapy using TPF protocol has been showed efficacy in the neo-adjuvant setting for head and neck squamous cell carcinoma (SCC) so far. However, effectiveness of concomitant chemoradiotherapy (CCRT) using TPF protocol has not yet been clearly distinguished. On the other hand, prognoses of the patients with advanced stage SCC of the ear invading extra-temporal bone were very poor. The aim of this study was to determine the safety and efficacy of newly developed CCRT using TPF protocol in patients with SCC of the temporal bone. Methods: Patients with previously untreated T4 disease were eligible for the study. Eleven patients were enrolled between December 2001 and August 2010. Treatment consisted of radiotherapy administered once daily to a total dose of 70 Gy, concomitant with 120 hour infusions of 5-FU (600 mg/m 2 /day), docetaxel (50 mg/m 2 , day 2) and cisplatin (60 mg/m 2 , day 2) given during first and fifth weeks of radiotherapy. These drug doses were determined from the results of our former phase I study to assess the dose limiting toxicity of this protocol. Median follow-up period was 33 months. Results: Nine patients completed this protocol. Bone marrow suppression was the most common adverse event observed through this study. Grade 4 leukopenia and neutropenia were observed in 1 (9%) and 3 (27%) of the patients and also those grade 3 events were observed in 3 (27%) and 1 (9%) of the patients. Grade 3 lymphopenia and hemoglobin were observed in 7 (64%) and 1(9%) patients. Although all patients showed dermatitis and alopecia at any grade, other grade 3 or 4 adverse events were obviously less than in patients with oropharyngeal or hypopharyngeal cancer using the same treatment protocol during the same period. Complete remission of primary tumor was obtained in all patients but one who rejected second course of TPF. Local recurrences were observed in three patients and one of them underwent salvage surgery. The disease-specific and over-all survival rates at 60 months of the patients were 77.8% and 70.7%, respectively. Conclusions: Our data suggested that CCRT using TPF protocol was feasible and very effective in patients with advanced stage SCC of the ear and temporal bone.
ASXL2 Is Recurrently Mutated in t(8;21) AML and Regulates Hematopoietic Development
Authors: Vikas Madan, Lin Han, Norimichi Hattori, Anand Mayakonda, Qiao-Yang Sun, Ling-Wen Ding, Hazimah Binte Mohd Nordin, Su Lin Lim, Weoi Woon Teoh, Pavithra Shyamsunder, Janani Sundaresan, Ngan B. Doan, Masashi Sanada, Aiko Sato-Otsubo, Li-Zhen Liu, Henry Yang, Jonathan W. Said, Seishi Ogawa, Der-Cherng Liang, Lee-Yung Shih, Tsuyoshi Nakamaki, Q. Tian Wang, H. Phillip Koeffler
Journal: Blood (2016)